Aligos Therapeutics(ALGS) - 2025 Q3 - Quarterly Results

EXHIBIT 99.1 Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2025. "Our Phase 2 B-SUPREME study of pevifoscorvir sodium (pevy) i ...